Metrics raised 1
- Bangalore ARPOB target raised to ₹80,000-85,000 (from prior guidance of ₹70,000-75,000)
Metrics cut 1
- ARPP long-term growth guidance cut to 4-5% CAGR (management states 6-7% inflation-based growth is 'too aggressive')
Event Participants
Executives
6 Bhaskara Rao Bollineni (Founder and Managing Director), Abhinay Bollineni (Executive Director and CEO), Sachin Salvi (CFO), Nitish Sethi (CEO, KIMS Bangalore cluster), Srinath Reddy (Director of Business Strategy), Vijay Suresh Hargunani (AVP, Business Planning & Growth)
Analysts
12 Alankar Garude (Kotak Securities), Damayanti Kerai (HSBC), Karan Vora (Goldman Sachs), Kunal Randeria (Axis Capital), Nancy Yadav (Allegro Capital Advisors), Rahul Jeewani (IIFL Capital), Sagar Jethwani (Phillip Capital PMS), Sandhya Deo (Unicorn Asset), Saurabh Kumar (Scientific Investing), Simran Thakkar (Beas Capital), Sukrit Patil (Eyesight Fintrade), Yuvraj Sehrawat (Chryscapital)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Revenue | ₹1,196 crore | +36.1% YoY, +10.3% QoQ; growth trajectory continued from ₹1,000+ crore run-rate achieved in Q3 FY26 |
| Revenue from Operations | ₹1,180 crore | +35.3% YoY, +9.8% QoQ; driven by strong IP/OP volume growth across clusters |
| EBITDA | ₹240 crore | +20.1% YoY, +10.9% QoQ; margin stable at 20.1% vs 20.27% YoY despite new unit drags |
| Consolidated EBITDA (pre-India, incl. other income) | ₹222 crore | +14.6% YoY, +12.9% QoQ |
| Consolidated EBITDA (pre-India, excl. other income) | ₹206 crore | +10.2% YoY, +10.0% QoQ |
| PAT | ₹37 crore | vs ₹85 crore Q1 FY26 and ₹33 crore Q4 FY26; impacted by new unit ramp-up costs and higher depreciation/interest |
| Cash & Cash Equivalents | ₹505 crore | As on 30 June 2026; includes bank balances and mutual fund investments <12 months |
| Net Debt | ₹2,400 crore | Reduced from ₹3,250 crore (Mar 31, 2026) to ₹2,570 crore (Jun 30, 2026) post QIP; further ₹100 crore repaid in early July |
| Avg Revenue per Operating Bed (ARPOB) | — | +9.7% YoY, +0.1% QoQ |
| Avg Revenue per Patient (ARPP) | — | +6.8% YoY, -3.8% QoQ; management flags ARPP as more reliable metric than ARPOB |
| IP Volumes | 72,493 | +26.6% YoY, +14.0% QoQ; annual growth 15.4% vs FY25 |
| OP Volumes | 6,58,617 | +28.5% YoY, +8.0% QoQ; annual growth 25.4% vs FY25 |
| EBITDA Margin | 20.1% | vs 20.27% Q1 FY26 and 19.9% Q4 FY26; stable despite ~₹4-5 crore pre-operative costs at new Kondapur |
Geographic & Segment Commentary
Telangana (mature cluster): Delivered strong YoY revenue and EBITDA growth in Q1, led by steady occupancy ramp-up. Cluster occupancy on functional beds (excluding 200 beds under renovation at Secunderabad and newly added Kondapur) stood at ~61%, with management confident of reaching 70% over 3-4 years. Kondapur (new facility) ran only 10 days in Q1 after first patient admission on June 20; July revenue surged 40% to ₹45 crore vs ~₹32-33 crore prior run-rate. Old Kondapur facility remains operational for ~6 months, incurring ₹90 lakh + GST monthly rental plus ₹3-4 crore annual operating cost as a temporary drag. Management expects 30-35% EBITDA margins from this cluster long-term; new clinical programs (oncology, transplant) being initiated at new Kondapur are expected to drive the ₹1,200 crore annual revenue potential over 4-5 years.
Karnataka (Bangalore cluster): Mahadevapura achieved EBITDA breakeven in less than 7 months (monthly breakeven from June, revenue ₹20 crore in July); Electronic City expected to turn positive in the next 1-2 quarters. Cluster targeting zero EBITDA loss for full FY27 with losses to be recouped. ARPOB is higher than initially guided (~90,000+ vs 70,000-75,000 guidance) because of complex, niche cardiac case mix; expected to stabilize at ₹80,000-85,000 once insurance empanelment and broader case mix normalizes. 40 beds added at Mahadevapura (170→210 operational beds), with further census-bed additions planned at 55-60% occupancy trigger.
Maharashtra (Nagpur, Nasik, Thane, Sangli): Nasik achieved EBITDA breakeven in Q1. Thane's ramp-up has been slower due to historically weak Q1 seasonality in Maharashtra and delayed insurance empanelment (GYPSA done in May, tumor in June); July revenue jumped to ₹21 crore vs ~₹16 crore Q1 average with 10% EBITDA margin, which management expects to sustain and improve in Q2. Nagpur clocked ₹30 crore in July, highest ever. Doctor recruitment follows a part-time-to-full-time migration model in Maharashtra, making ramp-up structurally slower than South India; management is confident of 20%+ revenue growth and healthy margins as assets stabilize.
Kerala: Three operational units following the new Palakkad opening (total capex ₹110 crore), with Thrissur commissioning expected in the next 3-4 months. Cluster currently at single-digit EBITDA margins, expected to remain so through FY27, move to mid-teens in FY28, and stabilize at 20-22% over 2-3 years, partly due to 4-5% rental costs on leased assets. Revenue run-rate around ₹77 crore; full year-end margin trajectory expected to improve with Thrissur ramp-up.
Andhra Pradesh: Growth continued in Q1, though quarterly QoQ growth moderated slightly due to seasonal case mix changes. Management sees no alarming structural issues; oncology services have been added across most AP hospitals in the last 2-3 months, expected to provide an incremental growth arc. O&M agreements signed for two hospitals in Telangana (300-bed, ~₹30-35 crore monthly, near new Kondapur) and an Andhra micro-market (current ~₹78 crore, scalable to ₹15-20 crore); management receives a percentage of top-line only, with no P&L drag.
Company-Specific & Strategic Commentary
Balance Sheet Strengthening & QIP: Raised ₹1,500 crore via QIP (oversubscribed, closed June 24), of which ₹1,100 crore was utilized to repay secured debt by June 27-28; additional ₹100 crore retired in early July, taking net debt to ~₹2,400 crore. Interest cost savings will be visible from Q2 FY27 onwards. QIP proceeds and promoter preferential allotment (₹600 crore; 25% upfront, balance within 18 months) position the company with adequate leverage headroom for expansion.
New Facility Ramp-Up: Kondapur (450 beds commissioned in late June) delivered 40% revenue growth in its first full month; pre-operative costs of ₹4-5 crore in Q1 will compress as revenue scales. Thrissur to commence in 3-4 months. Management's priority for the next three quarters is stabilizing commissioned hospitals and turning them EBITDA positive; new greenfield projects may be announced in FY28, restricted to core geographies (Telangana, Andhra, Maharashtra, Karnataka, Kerala) with acquisition targets of 300-350 bed hospitals.
Clinical Excellence & Brand Milestones: Dr. Raghuram secured a third Guinness World Record in 15 months for AI-enabled holographic health education; KIMS Nagpur performed the first robotic (DaVinci) implantation of a sutureless aortic valve in India/APAC; Dr. Mehta presented a novel surgical technique (no shunt, no hypothermia, no bypass) at the Vascular Annual Meeting 2026 in Boston. A dedicated sports ortho clinic was inaugurated at Vizag — first of its kind in Andhra Pradesh.
O&M Agreements & Consolidation Pipeline: Board approved O&M call option agreements with Golden Lands Solutions and Tagotam Healthcare for two hospitals in Telangana and Andhra. This asset-light structure provides top-line contribution without P&L losses, with call options to acquire once ramp-up is demonstrated. Management may pursue brownfield consolidation opportunities in Kerala, Telangana, and Maharashtra.
Insurance Empanelment Progress: Empanelment traction improved materially: big-ticket empanelments (key insurers) for Sangli, Nasik, and the two Bangalore assets expected by end-August to mid-September, with ~50% of insurers now empanelled. Earlier uncertainty around timelines has been replaced with definitive schedules; GIC's common empanelment framework is expected to settle over the next few months.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Bangalore Cluster EBITDA | Zero EBITDA for full FY27 (losses recouped) | Mahadevapura already at breakeven; Electronic City expected positive by year-end |
| Maharashtra Clusters | 20%+ YoY revenue growth; healthy EBITDA after stabilization | Thane July run-rate of ₹21 crore with 10% margin expected to sustain; ramp-up structural (part-time to full-time doctors) |
| Kerala EBITDA Margin | Single-digit FY27; mid-teens FY28; 20-22% stabilization in 2-3 years | Rental cost of 4-5% knocks off margin; Thrissur commissioning in 3-4 months |
| Kondapur Revenue Potential | ~₹1,200 crore annual revenue (₹100 crore/month) in 4-5 years; 30% EBITDA margin | Clinical program expansion (oncology, transplant) and new talent; margins suppressed in first 2 years |
| ARPP Growth | 4-5% long-term CAGR | Management explicitly stated 6-7% inflation-based growth is "too aggressive" |
| Bangalore ARPOB | Model at ₹80,000-85,000 (vs ~₹90,000+ current) | Higher current levels due to complex case mix; will normalize as empanelment and broader case mix progress |
| Telangana Occupancy | 70% achievable in 3-4 years; current ~61% on functional beds | Excludes 200 Secunderabad beds under renovation and new Kondapur beds |
| Group EBITDA Margin (mature Telangana) | 30-35% | FY25/FY26 delivered 31%; Sunshine Q4 at 38-39%; back-half recovery depends on new unit ramp-up |
| Capex | ₹100-125 crore over next 9 months | Includes Secunderabad new build, Rajamundry (₹60-75 crore), and Kondapur residual; maintenance capex ~₹100 crore/year |
| Debt-Equity Ratio | Maintain ~2.5:1 | Internal accruals to be deployed for greenfield/brownfield expansion in core clusters |
| Minority Interest | 10-15% of PAT over longer term | Current quarter at 10.5% |
Risks & Constraints
| Risk | Context |
|---|---|
| Insurance Empanelment Delay | Q1 was significantly impacted by delay in empanelment (GYPSA in May, tumor in June for Thane). Management now has definitive timelines — key insurers by end-August/mid-September, with ~50% empanelled. Remaining delay would suppress new unit revenue ramp-up. |
| New Unit Ramp-Up Execution | Combined drag from Kondapur (pre-operative costs ₹4-5 crore), old Kondapur facility (₹90 lakh + GST monthly rent plus ₹3-4 crore operating cost for ~6 months), and Electronic City losses. If ramp-up trails expectations, EBITDA margin compression extends beyond FY27. |
| Government Receivables | Cash flow pressure from delayed government payouts has been a persistent challenge; management noted a positive trend of receivables coming on time "to a certain extent." |
| Regulation & GIC Empanelment Framework | GIC's common empanelment initiative coincided with KIMS's new hospital commissioning and was a headwind last year. Some clarity is emerging; management expects the framework to settle within months but avoids public commentary. |
| Structural Slower Maharashtra Ramp-Up | Doctor alignment in Maharashtra follows a slower part-time-to-full-time migration model, making hospital ramp-ups structurally slower than in South India. Management cites 18-24 months to stabilize acquired units (e.g., Nagpur). |
| Margin Dilution from New Capacity | Group EBITDA margin held at 20.1% in Q1, but new capacity (Kondapur, Thrissur, Bangalore) will continue to dilute margins until full ramp-up; management targets 30-35% on mature Telangana but timing depends on new units maturing. |
| Balance Sheet Leverage | Debt at ~₹2,400 crore post-QIP; management intends to keep debt-equity at 2.5:1. Aggressive greenfield/M&A in core clusters could stretch leverage if internal accruals fall short or acquisitions close simultaneously. |
Q&A Highlights
Execution Priorities and Risk Management
- Question: Beyond regular outlook, what are the top 2-3 execution priorities and biggest risks to patient demand/competitive pressures? (Sukrit Patil, Eyesight Fintrade)
- Answer: Focus is on the new Kondapur hospital (40% growth in first month), Thrissur (commissioning in 3-4 months), and neutralizing all last year's commissioned hospitals. On risk, QIP proceeds have repaid secured loans providing leverage headroom; government receivables are coming on time; loss funding reduced for newer units, with ramp-up speed the key variable. (Abhinay Bollineni, Sachin Salvi)
Kerala Margins and ARPOB vs ARPP
- Question: How to attribute cost increases in Kerala units, and is the RPOB jump a steady state or quarterly phenomenon? (Sandhya Deo, Unicorn Asset)
- Answer: Kerala is in growth phase—single-digit EBITDA this year, mid-teens next year, 20-22% in 2-3 years. ARPOB changes reflect seasonal case mixing; ARPP (6.8% YoY growth) is the more reliable metric. Mature Telangana/Andhra clusters delivered strong YoY revenue and EBITDA growth. (Abhinay Bollineni)
Capex Strategy and Telangana Occupancy
- Question: Is expansion broadly done, or are there more markets? Why is Telangana occupancy hovering at 50-52%? (Damayanti Kerai, HSBC)
- Answer: Priority for the next 3 quarters is stabilizing current hospitals; greenfield opportunities will come in FY28 within core geographies. Telangana occupancy is optically depressed—250 beds at Secunderabad demolished (shown in capacity but not operational), new facility ready by end of next year. On functional beds, occupancy is ~61%, with 70% doable in 3-4 years despite Kondapur. (Abhinay Bollineni)
Debt Repayment and Insurance Empanelment Timelines
- Question: Should we assume considerable interest expense reduction from Q2, and what is empanelment status? (Damayanti Kerai, HSBC)
- Answer: QIP proceeds received June 24 and debt repayment happened June 27-28; interest savings will show from this quarter onwards. Empanelment progress is strong—50% of insurers done; key remaining empanelments (Sangli, Nasik, two Bangalore assets) to complete by end-August/mid-September with definitive timelines. (Sachin Salvi; Abhinay Bollineni)
Kondapur Losses and Bangalore ARPOB
- Question: How were margins maintained flat YoY despite adding 450 operational beds, and is the 90,000+ RPOP the right base? (Karan Vora, Goldman Sachs)
- Answer: Marginal losses in Q1—pre-operative costs of ₹2 crore/month; July revenue surged to ₹45 crore and no significant losses anticipated even with old hospital still running (~6 months). Bangalore ARPOB is high (₹90,000+) due to complex niche cardiac cases; should stabilize to ₹80,000-85,000 as empanelments and case mix broaden. (Abhinay Bollineni; Vijay Suresh Hargunani)
Thane Ramp-Up and Bangalore Breakeven
- Question: Thane EBITDA losses flattened for 3 quarters—what's happening, and when for Bangalore breakeven? (Rahul Jeewani, IIFL Capital)
- Answer: Maharashtra Q1 is traditionally weak and empanelment delays held back Thane. July revenue was ₹21 crore vs ₹16 crore Q1 average with 10% EBITDA margin; trajectory continuing into August, so breakeven on quarterly basis achievable in Q2. Mahadevapura already breakeven (₹20 crore July revenue); Electronic City by year-end. Bangalore cluster targeting zero losses for the year. (Abhinay Bollineni)
Kondapur Revenue Potential and Maharashtra vs South Differences
- Question: What drives ₹100 crore/month potential for Kondapur, and why is Mahadevapura outpacing Thane? (Kunal Randeria, Axis Capital)
- Answer: Kondapur lacked space for oncology and transplant; new facility solves for clinical program expansion and attracting new leaders. Full potential ₹1,200 crore annual revenue in 4-5 years. Maharashtra is structurally slower because doctors must shut their own clinics/nursing homes to go full-time, unlike South India where talent moves between corporate hospitals; Nagpur took 18-24 months to stabilize and now delivers ₹30 crore/month. (Abhinay Bollineni)
Capacity Utilization and Margin Recovery Path
- Question: Occupancy is ~50%; when do we hit 55-60% and revert to 28%+ margins? Are we capped at 65%? (Saurabh Kumar, Scientific Investing)
- Answer: On the current 2,669-bed capacity, removing 450 new Kondapur beds and 200 Secunderabad beds under renovation, the existing cluster is already at 61% occupancy. Without further bed additions, FY30 shows 65-70% occupancy and ~30% EBITDA margins. (Abhinay Bollineni)
Minority Interest and Cash Flow Deployment
- Question: What minority interest should we factor, and will cash flows go to debt reduction or capex? (Saurabh Kumar, Scientific Investing)
- Answer: Minority interest 10.5% current quarter, 10-15% range over long term. Maintenance capex ₹100 crore/year. Operating cash flow of ₹2,500+ crore over 3-4 years will largely be deployed into greenfield/brownfield growth in core clusters, maintaining a 2.5:1 debt-equity target rather than aggressive deleveraging. (Sachin Salvi; Abhinay Bollineni)
Telangana Sustainable Margins and GIC Empanelment
- Question: Why 30% vs the historical 35% peak, and what's the update on common empanelment? (Alankar Garude, Kotak Securities)
- Answer: Telangana delivered 31% EBITDA in FY25 and FY26; mature sub-clusters (Secunderabad) run at 34-35%, Sunshine at 38-39% in Q4. New bed capacity (Kondapur, Secunderabad) will suppress margins near-term but 30-35% is sustainable. GIC common empanelment hit the market last year just as KIMS commissioned new hospitals; insurance companies are getting clarity, and the framework should settle in the next few months. (Abhinay Bollineni)
Old Kondapur Costs and Kondapur Margin Modeling
- Question: What is the old hospital's rental cost and how long will it last? What EBITDA margin for new Kondapur? (Rahul Jeewani, IIFL Capital)
- Answer: Old facility runs for another ~6 months, ₹90 lakh + GST monthly rent plus ₹3-4 crore annual operational cost. Model Kondapur at ~30% EBITDA margin at ₹1,200 crore revenue; 35-40% would require more maturity time for the new clinical programs. (Abhinay Bollineni)
Key Takeaway
KIMS delivered a strong Q1 FY27 with total revenue of ₹1,196 crore (+36.1% YoY), EBITDA of ₹240 crore (+20.1% YoY) at a stable 20.1% margin, and PAT of ₹37 crore, despite ~₹4-5 crore pre-operative costs at the newly commissioned Kondapur facility and continued drag from Electronic City, Thane, and the soon-to-be-closed old Kondapur unit. The ₹1,500 crore QIP (oversubscribed) and ₹600 crore promoter preferential allotment have already reduced net debt to ~₹2,400 crore, with interest savings visible from Q2. Strategy centers on stabilizing commissioned hospitals—Mahadevapura has achieved breakeven in under 7 months, Thane reached ₹21 crore monthly revenue with 10% EBITDA in July, and Kerala is adding Thrissur in the next 3-4 months—while new greenfield announcements are deferred to FY28 within core geographies. Telangana's ~61% functional occupancy and 30-35% mature cluster EBITDA margins underpin the medium-term profitability path, with Kondapur's ₹1,200 crore annual revenue potential as the biggest stock catalyst. Key watch items include completion of remaining insurance empanelments by mid-September, Electronic City breakeven by year-end, and avoidance of further margin dilution as new capacity matures.
Transcript incomplete — no webcast/slide-specific references beyond transcript data; all figures and commentary derived from the available call text.